



# Cervical Cancer Screening and Management Recommendations for Individuals 21 to <25 Years of Age With a Cervix

[Click here for topics associated with this algorithm](#)

Strategy Based on 2014 ASCCP Recommendations<sup>a</sup>



Strategy Based on 2020 ACS Recommendations



**Abbreviations**

|        |  |
|--------|--|
| ASC-US | Atypical squamous cells of undetermined significance   |
| ASCCP  | American Society for Colposcopy and Cervical Pathology |
| ACS    | American Cancer Society                                |
| CIN2   | Cervical squamous intraepithelial neoplasia 2          |
| hrHPV  | High-risk HPV  |
| HPV    | Human papillomavirus                                   |
| LSIL   | Low-grade squamous intraepithelial lesion              |
| NAA    | Nucleic acid amplification                             |

<sup>a</sup>Screening is not recommended for individuals who are posthysterectomy with no history of cervical cancer or CIN2+.

**References**  
 Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. *CA Cancer J Clin.* 2020;70(5):321-346.  
 Huh WK, Ault KA, Chelmow D, Davey DD, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. *Gynecol Oncol.* 2015;136(2):178-182.  
 Massad S, Einstein MH, Huh WK, et al. 2012 ASCCP consensus guidelines conference. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors *Obstet Gynecol.* 2013;121(4):829-846.  
 The American Society for Colposcopy and Cervical Pathology. [Cervical cancer screening recommendations, 2014](#). [Updated: Aug 2014; Accessed: Apr 2020]